Thermo Fisher Q1 Beats, But Underlying Headwinds Persist

What happened

Thermo Fisher reported Q1 revenue of $11.01B (+6%) and adjusted EPS of $5.44 (+6%), marginally ahead of expectations. However, the growth was entirely driven by pharma/biotech demand, while academic/government instruments continued to decline due to funding uncertainty. Management maintained its FY2026 guidance for 3-4% organic growth and adjusted EPS of $24.22-24.80, but the tariff/FX headwind in Analytical Instruments remains a drag on margins. The Clario acquisition is on track for mid-2026 close, yet regulatory unknowns linger. Overall, the results validate the base case but do not resolve the key risks of academic weakness and margin pressure.

Implication

The stock has fallen below the previously identified attractive entry ($470), but without confirmation that headwinds are contained, the risk/reward remains balanced. Accumulate only if Q2 shows stabilization in academic funding and tariff/FX headwinds ease, or if Clario closes with clear synergy potential.

Thesis delta

Q1 results confirm the base case but do not reduce the downside risks from academic weakness and tariff/FX margin erosion. The WAIT thesis remains intact; the stock’s decline improves potential upside but requires evidence of stabilization before committing capital. The next three months are decisive for both academic funding trends and Clario approval progress.